Fulgent Genetics (FLGT) CSO logs RSU awards and tax share withholdings

Rhea-AI Filing Summary

Fulgent Genetics Chief Scientific Officer Hanlin Gao reported equity awards and related tax withholdings in company stock. On February 24, 2026, he acquired 4,891, 12,762, 22,806 and 26,661 shares of common stock at $0 per share through grants and vesting of restricted stock units, including performance-based awards tied to milestones from grants made in 2023, 2024 and 2025.

To cover tax obligations from these vestings, 2,489, 4,661, 8,149 and 403 shares were withheld at prices of about $23.09 and $23.01 per share. After these transactions, Gao directly owned 976,316 to 1,002,977 shares across the reported line items, reflecting routine compensation-related activity rather than open-market buying or selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		403(1)	D	$23.01	951,156	D
Common Stock	02/24/2026		A		4,891(2)	A	$0	956,047	D
Common Stock	02/24/2026		A		12,762(3)	A	$0	968,809	D
Common Stock	02/24/2026		A		22,806(4)	A	$0	991,615	D
Common Stock	02/24/2026		F		2,489(5)	D	$23.09	989,126	D
Common Stock	02/24/2026		F		4,661(6)	D	$23.09	984,465	D
Common Stock	02/24/2026		F		8,149(7)	D	$23.09	976,316	D
Common Stock	02/24/2026		A		26,661(8)	A	$0	1,002,977	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

2. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023.

3. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024.

4. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025.

5. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023.

6. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024.

7. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025.

8. Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

	/s/ Paul Kim as Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FLGT Chief Scientific Officer Hanlin Gao report in this Form 4?

Hanlin Gao reported grants and vesting of restricted stock units in Fulgent Genetics common stock, along with share withholdings to cover tax obligations. These transactions reflect compensation-related equity awards rather than open-market buying or selling activity.

How many Fulgent Genetics (FLGT) shares did Hanlin Gao acquire in equity awards?

On February 24, 2026, Hanlin Gao acquired 4,891, 12,762, 22,806 and 26,661 FLGT common shares at zero cost through grants and vesting of restricted stock units. These included performance-based awards tied to milestones from grants made in 2023, 2024 and 2025.

Were any of Hanlin Gao’s FLGT share transactions open-market sales?

No, the reported dispositions used code F, indicating shares were withheld to satisfy tax liabilities from vesting restricted stock units. This means the shares were not sold in open-market transactions but retained by the issuer to cover required taxes.

Why were some FLGT shares withheld from Hanlin Gao in this filing?

Shares were withheld to satisfy tax withholding obligations triggered by vesting of previously granted restricted stock units. The filing notes shares from February 23, 2023, February 26, 2024 and February 25, 2025 grants were partially withheld to pay these tax liabilities in stock.

What type of equity awards did Hanlin Gao receive from Fulgent Genetics (FLGT)?

The filing describes performance-based restricted stock units that vested upon meeting specified performance milestones, as well as time-based restricted stock units vesting over three years. One RSU grant begins vesting 12 months after March 1, 2026, then quarterly over the following 24 months.

How does this Form 4 affect Hanlin Gao’s ownership of FLGT shares?

After the reported grants, vesting and tax-related withholdings, Hanlin Gao’s direct ownership moved around the one-million-share level across the line items. The activity mainly reflects equity compensation mechanics, rather than a directional change from discretionary market buying or selling.